Onconova Therapeutics, Inc. to Present at Two Investor Conferences in February
February 09 2017 - 8:30AM
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage
biopharmaceutical company focused on discovering and developing
novel products to treat cancer, today announced that Dr. Ramesh
Kumar, President & CEO, will present a Company overview at:
- 19th Annual BIO CEO & Investor Conference
- SeeThruEquity 3rd Annual Innovations Investor Conference
Presentation Details:
BIO CEO & Investor Conference
Date: Monday, February 13th, 2017 Time: 3:00 PM Room: Park South
at the Waldorf Astoria in New York City
A recording of the presentation will be available on Onconova’s
website or via this link approximately one hour after the live
event. The link will be accessible until May 15th, 2017.
SeeThruEquity 3rd Annual Innovations Investor
Conference
Date: Wednesday, February 22nd, 2017 Time: 11:00 AM W Hotel in
South Beach, FL
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a Phase 3 stage
biopharmaceutical company focused on discovering and developing
novel small molecule drug candidates to treat cancer, with a
primary focus on Myelodysplastic Syndromes (MDS). Rigosertib,
Onconova’s lead candidate, is a proprietary phase 3 small molecule
agent, blocking cellular signaling by acting as a Ras
mimetic. Using a proprietary chemistry platform, Onconova has
created a pipeline of targeted anti-cancer agents designed to work
against specific cellular pathways that are important in cancer
cells, while causing minimal damage to normal cells. Onconova
has three product candidates in clinical trials and several
active pre-clinical programs. Advanced clinical trials with
our lead compound, rigosertib, are aimed at unmet medical
needs of patients with MDS. For more information, please visit
http://www.onconova.com.
Forward Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, Section 21E of the Securities Exchange Act of
1934, as amended, and the Private Securities Litigation Reform Act
of 1995, which involve risks and uncertainties. These statements
relate to future events or Onconova Therapeutics, Inc.'s future
operations, clinical development of Onconova's product candidates
and presentation of data with respect thereto, regulatory
approvals, expectations regarding the sufficiency of Onconova's
cash and other resources to fund operating expenses and capital
expenditures, Onconova's anticipated milestones and future
expectations and plans and prospects. Although Onconova believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, expectations may prove to have
been materially different from the results expressed or implied by
such forward-looking statements. Onconova has attempted to identify
forward-looking statements by terminology including "believes,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "should," "approximately" or other words that
convey uncertainty of future events or outcomes. These statements
are only predictions and involve known and unknown risks,
uncertainties, and other factors, including Onconova's need for
additional financing and current plans and future needs to scale
back operations if adequate financing is not obtained, the success
and timing of Onconova's clinical trials and regulatory approval of
protocols, and those discussed under the heading "Risk Factors" in
Onconova's most recent Annual Report on Form 10-K and quarterly
reports on Form 10-Q. Any forward-looking statements contained in
this release speak only as of its date. Onconova undertakes no
obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
GENERAL CONTACT:
http://www.onconova.com/contact/
INVESTOR RELATIONS CONTACT:
Lisa Sher, MBS Value Partners on behalf of Onconova Therapeutics
Lisa.Sher@mbsvalue.com
(212) 750-5800
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Sep 2023 to Sep 2024